10 results about "Atypical mycobacterium" patented technology

Provided herein are method of treating a patient with nontuberculous mycobacteria by administering nitric oxide to the patient for at least 100 days to increase functional capacity and quality of life of the patient.

A novel CHI3L1 inhibitor provided in the present invention can efficiently inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1. In particular, it has been identified that K284-6111 can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1, and by newly synthesizing derivatives of K284-6111, novel compounds having a CHI3L1 inhibitory ability superior to that of K284-6111 have been identified. Therefore, the novel CHI3L1 inhibitors provided in the present invention can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1.

The chitinase 3-like 1 (CHI3L1) inhibitor, specifically kasugamycin, provided by the present invention, suppresses the expression or activation of chitinase 3-like 1 (CHI3L1), thereby effectively preventing or treating infections with acid-fast bacteria, particularly non-tuberculous mycobacteria and various diseases caused by infection with acid-fast bacteria, particularly nontuberculous mycobacteria. In addition, by measuring the expression level of chitinase 3-like 1 (CHI3L1) protein, when the expression level is higher than that of a control group, it is possible to effectively predict infection with acid-fast bacteria, particularly non-tuberculous mycobacteria, the onset of diseases caused by infection with acid-fast bacteria, particularly non-tuberculous mycobacteria, or the prognosis of diseases related to infection with acid fast bacteria, particularly nontuberculous mycobacteria.

Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a Mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound of Formula I.

This invention relates to combinations for treating nontuberculous mycobacterial diseases. Specifically, it relates to combinations of bedaquiline, macrolides (e.g., clarithromycin), and optionally ethambutol for use in the treatment of diseases associated with nontuberculous mycobacteria (NTM).

Provided herein are methods for preventing or treating an infection caused by a Nontuberculous mycobacterium (NTM) species in a subject comprising administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide. Also provided in are methods for sensitizing a biofilm to an antibiotic agent, wherein the biofilm comprises a Nontuberculous mycobacterium (NTM) species, the method comprising contacting the biofilm with an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide.

The present invention relates to an immunogenic composition comprising a malonate semialdehyde decarboxylase (MSAD) protein or a polynucleotide encoding same, and a vaccine composition and a pharmaceutical composition for preventing or treating nontuberculous mycobacteria infection, which comprise same. The vaccine composition and the pharmaceutical composition, which comprise the MSAD protein or the polynucleotide encoding same, of the present invention, have excellent preventive and therapeutic efficacy against nontuberculous mycobacteria infection. In addition, the vaccine composition and the pharmaceutical composition, which comprise the MSAD protein or the polynucleotide encoding same, of the present invention, have a greater effect of preventing and treating nontuberculous mycobacteria infection when administered intranasally, and have a greater effect of preventing and treating nontuberculous mycobacteria infection when used in combination with an immune adjuvant.

According to the invention, systematic MIC determination is carried out on fast-growing and slow-growing nontuberculous mycobacteria, and it is found that TBA-7371 has stable low MIC in nontuberculous mycobacteria of different pedigree, so that it is technically ensured that TBA-7371 can reach an effective inhibitory concentration in vivo more easily and has broad-spectrum applicability. The invention further explores the combined medication effect of the TBA-7371 and a plurality of first-line anti-mycobacterium tuberculosis drugs, and finds that when the TBA-7371 is combined with other anti-tuberculosis drugs, the required concentrations of the other anti-tuberculosis drugs can be reduced.

The present invention aims to provide a method for rapidly, simply, and reliably identifying patients with nontuberculous mycobacterial lung disease (pulmonary NTM disease) compared to lung cancer patients, healthy controls, or chronic airway inflammatory diseases other than pulmonary NTM disease, as well as a marker to be used in this method. [Solution] According to the present invention, it is possible to provide a biomarker consisting of the SLC26A4 gene, the SLC26A4 protein, or the SLC26A4-AS1 gene for distinguishing between subjects with pulmonary NTM disease and lung cancer patients or healthy controls or chronic airway inflammatory diseases other than pulmonary NTM disease, a method of identification using the gene or protein, and a kit containing the gene.

This invention discloses the use of a pyridine derivative. Specifically, it discloses the use of substance X in the preparation of drugs for inhibiting nontuberculous mycobacteria, drugs for treating and / or preventing nontuberculous mycobacterial infections, nontuberculous mycobacterial inhibitors, or nontuberculous mycobacterial antibacterial agents, wherein substance X is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The pyridine derivative of this invention exhibits good inhibitory activity against nontuberculous mycobacteria, and has low cytotoxicity and good safety.